Get the Stockscreener App
11.57
3.18%
0.5499
Silence Therapeutics Plc Adr stock is traded at $11.57, with a volume of 39,907.
It is up +3.18% in the last 24 hours and up +12.13% over the past month.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
See More
Previous Close:
$11.02
Open:
$11.13
24h Volume:
39,907
Relative Volume:
0.10
Market Cap:
$539.89M
Revenue:
$840.00K
Net Income/Loss:
$-75.20M
P/E Ratio:
-7.2671
EPS:
-1.5921
Net Cash Flow:
$-65.69M
1W Performance:
+8.39%
1M Performance:
+12.13%
6M Performance:
+122.50%
1Y Performance:
+79.34%
1-Day Range:
$11.11
$11.86
1-Week Range:
$10.28
$11.90
52-Week Range:
$4.19
$11.90
Silence Therapeutics Plc Adr Stock (SLN) Company Profile
Name
Silence Therapeutics Plc Adr
Sector
Industry
Phone
44-0-20-3457 6900
Address
12 HAMMERSMITH GROVE, LONDON
Compare SLN vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLN
Silence Therapeutics Plc Adr
|
11.43 | 520.53M | 840.00K | -75.20M | -65.69M | -1.5921 |
VRTX
Vertex Pharmaceuticals Inc
|
485.15 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
674.16 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
907.15 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.28 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.62 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Silence Therapeutics Plc Adr Stock (SLN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-25 | Initiated | Goldman | Sell |
| Dec-02-24 | Reiterated | BMO Capital Markets | Outperform |
| Sep-03-24 | Initiated | Jefferies | Buy |
| Jan-31-24 | Initiated | BMO Capital Markets | Outperform |
Silence Therapeutics Plc Adr Stock (SLN) Latest News
SLN stock skyrockets 107% in six months: Here's what you need to know - MSN
Silence Therapeutics (SLN) moves 7.2% higher: Will this strength last? - MSN
ETFs Investing in Silence Therapeutics PLC Sponsored ADR Stocks - TradingView
SLN Stock Skyrockets 107% in Six Months: Here's What You Need to Know - Yahoo Finance UK
Silence Therapeutics (SLN) Moves 7.2% Higher: Will This Strength Last? - Yahoo Finance Singapore
Form 13D/A Silence Therapeutics Plc For: 8 July By Investing.com - Investing.com South Africa
Silence Therapeutics (SLN) surges 26.0%: Is this an indication of further gains? - MSN
Silence Therapeutics PLC Sponsored ADR Actuals & Estimates (NASDAQ:SLN) - TradingView
Silence Therapeutics (SLN) Surges 26.0%: Is This an Indication of Further Gains? - Yahoo Finance Singapore
Why is Silence Therapeutics stock surging today? - Investing.com
Silence Therapeutics stock jumps on Cantor Fitzgerald upgrade - Investing.com
Form 8K Silence Therapeutics plc For: 23 June By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Silence Therapeutics stock rating at buy By Investing.com - Investing.com India
H.C. Wainwright reiterates Silence Therapeutics stock rating at buy - Investing.com
Silence Therapeutics Stock Rises On Positive Blood Cancer Drug Data - Sahm
Silence Therapeutics presents divesiran trial data at EHA By Investing.com - Investing.com South Africa
Silence Therapeutics presents divesiran trial data at EHA - Investing.com
Silence Therapeutics (SLN) soars 19.0%: Is further upside left in the stock? - MSN
SLNSilence Therapeutics Plc ADR Stock Price and Quote - Finviz
Silence Therapeutics (NASDAQ: SLN) registers $300M shelf, $100M ADSs included - Stock Titan
Silence Therapeutics to Participate in H.C. Wainwright BioConnect Investor Conference - ChartMill
Revenue per share of Silence Therapeutics PLC Sponsored ADR – DUS:XRP2 - TradingView
Book value per share of Silence Therapeutics PLC Sponsored ADR – DUS:XRP2 - TradingView
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Short Interest Up 13.3% in April - MarketBeat
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Silence Therapeutics (NASDAQ:SLN) Shares Down 1.8%Here's What Happened - MarketBeat
Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a Bet - MSN
Polycythemia Vera Market Set for Transformation: Key 9 Companies Expected to Enter by 2036 | DelveInsight - GlobeNewswire Inc.
Silence Therapeutics (SLN) Soars 19.0%: Is Further Upside Left in the Stock? - Yahoo Finance
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Given Average Recommendation of "Moderate Buy" by Brokerages - marketbeat.com
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Why Urgent.ly Shares Are Trading Higher By Around 159%; Here Are 20 Stocks Moving Premarket - Benzinga
What is HC Wainwright's Estimate for SLN FY2030 Earnings? - MarketBeat
What is HC Wainwright’s Estimate for SLN FY2030 Earnings? - Defense World
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Silence Therapeutics Plc Adr Stock (SLN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.58%
1.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):